Tags

Type your tag names separated by a space and hit enter

Emerging therapeutic interventions for idiopathic pulmonary fibrosis.
Expert Opin Investig Drugs 2014; 23(7):893-910EO

Abstract

INTRODUCTION

Idiopathic pulmonary fibrosis (IPF) is a devastating and relentlessly progressive lung disorder. Previously, it was thought to be a chronic inflammatory disease; however, it is now considered to be an epithelial-fibroblastic disease. In accordance with this paradigm change, efforts toward the development of novel therapeutic targets for IPF have acquired a new direction. Currently available therapies are largely ineffective in reversing the lung damage, and lung transplantation is the only effective treatment for end-stage disease. Limitations in advancement of IPF therapeutics are due to a poor understanding of its pathogenesis, unavailability of reliable animal models and slow disease progression. Recent research on IPF has resulted in the identification of a plethora of novel targets that are in various stages of development and offers hope that in the near future that there will be better therapeutic options available for the treatment of IPF.

AREAS COVERED

This review discusses existing therapies and highlights some of the recent, novel therapeutics being explored in the current clinical landscape for the treatment of this chronic, disabling disorder. The review also discusses the pathogenic rationale behind current therapies.

EXPERT OPINION

Targeting one fibrotic signaling pathway at a time may not have any significant effect on the control of IPF. It is therefore recommended that future IPF management focuses on targeting multiple pro-fibrotic pathways associated with its complex pathogenesis.

Authors+Show Affiliations

Daiichi Sankyo India Pharma Pvt Ltd, Department of Biology , Village Sarhaul, Sector-18, UdyogVihar Industrial Area, Gurgaon-122 015, Haryana , India.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

24766571

Citation

Chakraborty, Sushmita, et al. "Emerging Therapeutic Interventions for Idiopathic Pulmonary Fibrosis." Expert Opinion On Investigational Drugs, vol. 23, no. 7, 2014, pp. 893-910.
Chakraborty S, Chopra P, Ambi SV, et al. Emerging therapeutic interventions for idiopathic pulmonary fibrosis. Expert Opin Investig Drugs. 2014;23(7):893-910.
Chakraborty, S., Chopra, P., Ambi, S. V., Dastidar, S. G., & Ray, A. (2014). Emerging therapeutic interventions for idiopathic pulmonary fibrosis. Expert Opinion On Investigational Drugs, 23(7), pp. 893-910. doi:10.1517/13543784.2014.913569.
Chakraborty S, et al. Emerging Therapeutic Interventions for Idiopathic Pulmonary Fibrosis. Expert Opin Investig Drugs. 2014;23(7):893-910. PubMed PMID: 24766571.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Emerging therapeutic interventions for idiopathic pulmonary fibrosis. AU - Chakraborty,Sushmita, AU - Chopra,Puneet, AU - Ambi,Senthil V, AU - Dastidar,Sunanda G, AU - Ray,Abhijit, Y1 - 2014/04/28/ PY - 2014/4/29/entrez PY - 2014/4/29/pubmed PY - 2015/1/24/medline KW - anti-fibrotic agents KW - apoptosis KW - idiopathic pulmonary fibrosis KW - inflammation KW - pulmonary fibrosis SP - 893 EP - 910 JF - Expert opinion on investigational drugs JO - Expert Opin Investig Drugs VL - 23 IS - 7 N2 - INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a devastating and relentlessly progressive lung disorder. Previously, it was thought to be a chronic inflammatory disease; however, it is now considered to be an epithelial-fibroblastic disease. In accordance with this paradigm change, efforts toward the development of novel therapeutic targets for IPF have acquired a new direction. Currently available therapies are largely ineffective in reversing the lung damage, and lung transplantation is the only effective treatment for end-stage disease. Limitations in advancement of IPF therapeutics are due to a poor understanding of its pathogenesis, unavailability of reliable animal models and slow disease progression. Recent research on IPF has resulted in the identification of a plethora of novel targets that are in various stages of development and offers hope that in the near future that there will be better therapeutic options available for the treatment of IPF. AREAS COVERED: This review discusses existing therapies and highlights some of the recent, novel therapeutics being explored in the current clinical landscape for the treatment of this chronic, disabling disorder. The review also discusses the pathogenic rationale behind current therapies. EXPERT OPINION: Targeting one fibrotic signaling pathway at a time may not have any significant effect on the control of IPF. It is therefore recommended that future IPF management focuses on targeting multiple pro-fibrotic pathways associated with its complex pathogenesis. SN - 1744-7658 UR - https://www.unboundmedicine.com/medline/citation/24766571/Emerging_therapeutic_interventions_for_idiopathic_pulmonary_fibrosis_ L2 - http://www.tandfonline.com/doi/full/10.1517/13543784.2014.913569 DB - PRIME DP - Unbound Medicine ER -